Affiliation:
1. Tashkent Pediatric Medical Institute
2. Republican AIDS Cente
Abstract
The aim of the study was to evaluate the diagnostic markers in children with HIV —encephalopathy (HIVE) with varying degrees of severity.Material and methods of research: The study included 260 children (153 boys — 58.85% and 107 girls —41.7%) with HIV-positive status and receiving antiretroviral therapy according to an individually selected scheme for at least 6 months. All children included in the study showed signs of HIV encephalopathy. The activity response was assessed by the concentration of IL-6, IL-10, TNF-alpha, C-reactive protein, C3, C4 components of the complement (immunofelometric analysis).Results: The study of the activity response in children with HIV encephalopathy found that the concentration of TNF —alpha and IL-6 were increased, compared, to the reference values (12.67±0.25 PG/ml and 23.04±0.64 PG/ml, respectively, with reference values of less than 8.1 PG/ml and 7pg/ml, respectively), and the concentration of IL-10 was reduced (5.93±0.10 PG/ml with a reference value of more than 9.1 PG/ml). The study analyzed the predictor significance of various parameters response in the aspect of the development of symptomatic HIV- encephalopathy. A comparative analysis of the concentration markers was performed, and the incidence of symptomatic HIV —encephalopathy was determined depending on the diagnostic concentration of the diagnostic marker. This finding is probably explained by the effector role of systemic inflammation in the development of damage to the Central nervous system.Conclusion. The maximum predictor significance in the aspect of the development of symptomatic HIV -encephalopathy was found in proinflammatory cytokines: an increase in IL-6 concentration above 19.6 PG / ml is associated with an increase in the risk of developing symptomatic HIV encephalopathy by 9.14 times, and an increase in TNF -alpha concentration above 12.5 PG/ml by 4.07 times (p<0.001 for both factors).
Reference24 articles.
1. UNAIDS. Global AIDS Update. Geneva: Joint United Nations Programme on HIV/AIDS; 2016. Global AIDS Update 2016.
2. UNAIDS. UNAIDS, ed Global AIDS Update. Geneva: Joint United Nations Programme on HIV/AIDS; 2017. UNAIDS Data 2017
3. Foster CJ, Biggs RL, Melvin D, et al: Neurodevelopmental outcomes in children with HIV infection under 3 years of age. Dev Med Child Neurol 48:677-682, 2006
4. Chiriboga CA, Fleishman S, Champion S, et al: Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr 146:402-407, 2005
5. Nachman SA, Chernoff M, Gona P, et al: Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med 163:164-171. http://dx.doi.org/10.1001/archpedi.163.2.164. [Erratum in: Arch Pediatr Adolesc Med. 2009 Apr;163(4):364]